[at Bloomberg] – Gilead Sciences Inc.’s hepatitis C pill Sovaldi led 27 new U.S. drug approvals this year, a “breakthrough” therapy being chased by competitors in 2014.
Read more on this.
Gilead Sciences Inc. … [visit site to read more]
Similar posts:- Gilead Sciences Inc. (NASDAQ:GILD) – Gilead to seek okay for combo hepatitis C pill in Q1
- Gilead Sciences Inc. (NASDAQ:GILD) – Gilead’s Hepatitis C Pill Works Better, FDA Report Says
- Stock Update: Johnson & Johnson (NYSE:JNJ) – J&J’s new hepatitis C drug gets positive FDA review